Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pilot assessment of low NK cell-mediated ADCC and FCGR3A genetics in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Based on inclusion of family members without ME/CFS as controls, low ADCC is unsuitable as a diagnostic biomarker

Alexander P. Sung, Jennifer J-J Tang, Michael J. Guglielmo, Julie Smith-Gagen, Lucinda Bateman, Doug D. Redelman, View ORCID ProfileDorothy Hudig
doi: https://doi.org/10.1101/2019.12.20.19015438
Alexander P. Sung
1University of Nevada, Reno School of Medicine, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer J-J Tang
1University of Nevada, Reno School of Medicine, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Guglielmo
1University of Nevada, Reno School of Medicine, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Smith-Gagen
2University of Nevada, Reno Health Sciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucinda Bateman
3Bateman Horne Center, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doug D. Redelman
†Deceased, University of Nevada, Reno School of Medicine, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothy Hudig
1University of Nevada, Reno School of Medicine, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dorothy Hudig
  • For correspondence: dhudig@unr.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

ADCC (antibody-dependent cell-mediated cytotoxicity) is dependent on the varying capacity of NK cells to kill, the affinities of FCGR3A-encoded CD16A receptors for antibody, and the presence of antigen-specific antibodies. In vivo ADCC depends on the number of CD16A receptor-positive NK cells in blood. We hypothesized that low ADCC cell function or low effector cell numbers could be biomarkers or risk factors for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). We measured NK cell ADCC lytic capacity and antibody recognition, CD16Apositive NK cells/µl blood, and FCGR3A homozygosity for the F allele that encodes low affinity CD16A antibody receptors. ME/CFS patients met the Fukuda 1994 diagnostic criteria. In this pilot report, we examined 5 families, each with 2 to 5 ME/CFS patients, and compared 11 patients, 22 family members without ME/CFS, and 16 unrelated healthy controls. ADCC was measured as CX1:1 cytotoxic capacity (the percentage of 51Cr-Daudi tumors with obinutuzumab anti-CD20 antibody that were killed at a 1:1 ratio of CD16Apos NKs to Daudis) and CX-slope. Individual CX1:1 capacities varied from 16.2% to 81.8% and were comparable between patients and unaffected family members, while the ADCC of both family groups was lower than the unrelated healthy controls. The lack of difference between patients and their unaffected family members indicates that low ADCC is unsuitable as a diagnostic biomarker for ME/CFS. Familial CD16Apos NK blood cell counts were lower than unrelated healthy controls. The potential for synergistic effects of combined low CX1:1 and low effector cell counts occurring in the same individual was 24-fold greater for CFS family members than for unrelated controls. FCGR3A of the families was predominantly F/F homozygous, correlating with the observed low EC50 for NK recognition of target cell-bound antibody. In summary, low ADCC is unsuitable as a biomarker, but could be a familial risk factor, for ME/CFS.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The research was supported in part by NIH R21 AI117491 awarded to DH as a coinvestigator, by NIH P30 GM110767 (Cytometry Center), and by an anonymous generous private donor to the Bateman Horne Center who helped pay for the collection and shipment of blood samples. We would also thank the Nevada INBRE program (NIH GM103440) for an undergraduate research scholarship (to APS) and supplies which helped support the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available upon request.

  • Abbreviations

    aa
    amino acid
    ADCC
    antibody-dependent cell-mediated cytotoxicity
    CD16A
    cluster of differentiation protein 16A, the IgG Fc-receptor of NK cells
    CFS
    chronic fatigue syndrome
    CX1:1
    the % cells killed at a 1:1 ratio of CD16Apositive NK cells to 51Cr-labeled Daudi cells with pre-bound obinutuzumab anti-CD20 mAb
    CX-slope
    cytotoxic slope as the effector cells are increased
    E:T
    effector to target cell ratio
    EC50
    the effective concentration of antibody needed for 50% of maximal ADCC
    FcR
    cellular receptor for the Fc region of immunoglobulin (antibody)
    FCGR3A
    the gene encoding CD16A, the IgG FcR of NK cells
    KIR
    killer cell immunoglobulin-like receptor
    ME
    myalgic encephalomyelitis
    NK
    natural killer lymphocyte
    LU50
    lytic unit50, the number of effector cells needed to kill 50% of the ‘target’ cells
    PBMC
    peripheral blood mononuclear cells
    ROC
    receiver-operating characteristic plot
    UHC
    unrelated healthy control subject
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted December 27, 2019.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Pilot assessment of low NK cell-mediated ADCC and FCGR3A genetics in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Based on inclusion of family members without ME/CFS as controls, low ADCC is unsuitable as a diagnostic biomarker
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Pilot assessment of low NK cell-mediated ADCC and FCGR3A genetics in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Based on inclusion of family members without ME/CFS as controls, low ADCC is unsuitable as a diagnostic biomarker
    Alexander P. Sung, Jennifer J-J Tang, Michael J. Guglielmo, Julie Smith-Gagen, Lucinda Bateman, Doug D. Redelman, Dorothy Hudig
    medRxiv 2019.12.20.19015438; doi: https://doi.org/10.1101/2019.12.20.19015438
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Pilot assessment of low NK cell-mediated ADCC and FCGR3A genetics in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Based on inclusion of family members without ME/CFS as controls, low ADCC is unsuitable as a diagnostic biomarker
    Alexander P. Sung, Jennifer J-J Tang, Michael J. Guglielmo, Julie Smith-Gagen, Lucinda Bateman, Doug D. Redelman, Dorothy Hudig
    medRxiv 2019.12.20.19015438; doi: https://doi.org/10.1101/2019.12.20.19015438

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Allergy and Immunology
    Subject Areas
    All Articles
    • Addiction Medicine (174)
    • Allergy and Immunology (419)
    • Anesthesia (97)
    • Cardiovascular Medicine (894)
    • Dentistry and Oral Medicine (166)
    • Dermatology (101)
    • Emergency Medicine (257)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
    • Epidemiology (8745)
    • Forensic Medicine (4)
    • Gastroenterology (403)
    • Genetic and Genomic Medicine (1845)
    • Geriatric Medicine (175)
    • Health Economics (386)
    • Health Informatics (1282)
    • Health Policy (642)
    • Health Systems and Quality Improvement (489)
    • Hematology (206)
    • HIV/AIDS (387)
    • Infectious Diseases (except HIV/AIDS) (10521)
    • Intensive Care and Critical Care Medicine (564)
    • Medical Education (193)
    • Medical Ethics (52)
    • Nephrology (216)
    • Neurology (1744)
    • Nursing (100)
    • Nutrition (264)
    • Obstetrics and Gynecology (342)
    • Occupational and Environmental Health (457)
    • Oncology (959)
    • Ophthalmology (279)
    • Orthopedics (107)
    • Otolaryngology (174)
    • Pain Medicine (117)
    • Palliative Medicine (41)
    • Pathology (262)
    • Pediatrics (553)
    • Pharmacology and Therapeutics (264)
    • Primary Care Research (218)
    • Psychiatry and Clinical Psychology (1836)
    • Public and Global Health (3963)
    • Radiology and Imaging (649)
    • Rehabilitation Medicine and Physical Therapy (340)
    • Respiratory Medicine (532)
    • Rheumatology (214)
    • Sexual and Reproductive Health (178)
    • Sports Medicine (165)
    • Surgery (196)
    • Toxicology (37)
    • Transplantation (105)
    • Urology (78)